Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Total Non-current Assets
All assets not expected to be converted to cash within one year.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets remains negative
Q1 FY2026 total non-current assets was $0, compared with $0 a year earlier.
Context
- Total non-current assets amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total non-current assets increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 824K | — |
Total Non-current Assets vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's Mar 2026 total non-current assets of $0 is the lowest of the 11 companies compared; the peer median is $21.49M.
- Total non-current assets amounts to 0.0% of total assets for NVCT, versus a peer median of 4.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $53.4B | +427956.3% | +60.0% | 24.9% | |
| Mar 2026 | $146.53M | +366.3% | +45.4% | 33.5% | |
| Mar 2026 | $35.35M | -16.8% | -18.2% | 16.2% | |
| Mar 2026 | $26.18M | -4.6% | +0.1% | 2.5% | |
| Mar 2026 | $24.9M | +255.8% | +119.4% | 10.9% | |
| Jun 2026 | $18.07M | -24.8% | +69.1% | 2.4% | |
| Mar 2026 | $9.48M | +29.8% | +26.3% | 4.6% | |
| Mar 2026 | $3.54M | +13.8% | +604.9% | 3.7% | |
| Mar 2026 | $1.49M | -98.4% | -39.8% | 0.3% | |
| Mar 2026 | $580K | -59.2% | -26.0% | 1.4% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding NVCT) | $21.49M | +4.6% | +35.8% | 4.2% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.